Skip to Main Content
Our Commitment to Diversity
Andrew D. Ruskin

Andrew Ruskin is a partner at the firm. He is a member of the Health Care and FDA practice group. Andy’s practice concentrates on the myriad ways that Medicare and Medicaid reimbursement and compliance shape the US health care ecosystem. Medicare and Medicaid regulations impact how health care providers and suppliers, and the entities that sell to them, such as drug and device manufacturers, structure themselves and their arrangements with each other. Health care and life sciences clients regularly seek Andy’s counsel on developing strategies that simultaneously address regulatory challenges while achieving organizational objectives. With almost a quarter century of practice representing clients in this area, Andy has examined, and solved for, a vast array of healthcare regulatory issues. His deep market knowledge allows Andy to simultaneously provide macro and micro perspectives on a health care client’s most challenging concerns. 

For health care providers, Andy provides practical guidance on compliance with a wide range of regulatory requirements, including the Provider Based Rule, rules governing graduate medical education, 340B compliance, and clinical trial reimbursement rules. Andy also provides experienced counsel on elections made for wage index purposes, including navigating rules pertaining to submissions to the Medicare Geographic Classification Review Board and to the CMS Regional Office for wage index and rural redesignations. Andy works with clients to closely examine billing rules to determine whether they have repayment obligations under the 60 Day Repayment Rule and assists in developing Compliance Program safeguards. Where clients disagree with the government’s assessment of their entitlement to payment, Andy represents them before regulatory tribunals, including the Provider Reimbursement Review Board, and defends them in Federal court proceedings and government investigations against claims involving False Claims Act liability. The complex regulatory requirements also serve as a backdrop to the advice he gives to clients when they seek his counsel developing provider affiliation agreements, joint venture agreements, and provider acquisitions. 

For drug and device manufacturers, Andy serves as a Market Access professional. His understanding of the drivers of Medicare and Medicaid payment, including Price Reporting concerns, and the program integrity risks associated with these payments, such as Anti-Kickback Statute and False Claims Act risk, allows him to be highly effective at negotiating agreements with distributors, group purchasing organizations, payors, 3PLs, and customers, as well as in presenting matters to the Centers for Medicare & Medicaid Services, where reimbursement for a product may not yet be optimal, in light of its value. Andy has appeared before the HCPCS Committee to assist with obtaining a new code. He also advises these entities on their Price Reporting policies, and Market Access policies, including their business rules pertaining to patient assistance programs, copay cards, and payments to foundations. Andy also assists with healthcare regulatory due diligence and strategizing for manufacturers seeking to acquire a product. Additionally, he defends manufacturers from False Claims Act liability where sales or marketing practices have been challenged.

A recognized thought leader and an active member of industry organizations, Andy serves as the current Chair of the American Health Law Association’s Institute on Medicare and Medicaid Payment Issues, is a member of the Health Law Advisory Committee to Wolters Kluwer CCH, and is on the Editorial Advisory Board to HCCA’s Report on Medicare Compliance. He is a sought-after speaker on current developments in Drug Pricing for such industry organizations as the American Conference Institute. 

Prior to joining the firm, Andrew counseled hospitals, pharmaceutical and medical device companies, and Medicare Advantage plans on a range of Medicare and Medicaid regulatory, litigation, and transactional matters. He advised on strategic issues surrounding coverage, reimbursement, and compliance, as well as drug pricing and price reporting. He defended clients in investigations by the U.S. Attorney’s Office and the Department of Health and Human Services Office of Inspector General. He has also appeared before several regulatory tribunals, such as the Provider Reimbursement Review Board and the HCPCS Committee.

  • Recognized by Chambers USA for Healthcare in District of Columbia, 2024
     
Additional Thought Leadership Pages
Additional News & Event Pages
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel